

ACTEMRA® PEDS ORDER FORM

FAX TO: 855.694.4656

PATIENT INFORMATION

PATIENT NAME:	PHONE:		
DATE OF BIRTH:	SEX: M F HEIGHT:	WEI	GHT: LBS
ALLERGIES:	PREFERRED CLINIC:		
REFERRAL STATUS: NEW REF	ERRAL ORDER CHANG	E ORDER RENE	EWAL
DIAGNOSIS & CLINICAL D	OCUMENTATION *	PLEASE COMPLETE	ICD-10 FOR SPECIFIC DIAGNOSIS
M08.2 Juvenile Rheumatoid Arthri	tis w/ Systemic Onset		
M08.3 Juvenile Rheumatoid Polyar	thritis (seronegative)		
ICD-10 CODE:	DESCRIPTION:		
	REQUIRED DO	OCUMENTATION	
Insurance List of Medications	Most recent History & Physical	Tried & Failed Therapies	Negative TB Negative Hep-B Screening
Liver Function Test results	Recent CBC w/ diff		
Tocilizumab - Actemra or biosimilar (Tyenro restrict substitution, indicate required brackers or Polyarticular JIA < 30 kg: Tocilizumab 10 mg/kg IV in 50 m ≥ 30 kg: Tocilizumab 8 mg/kg IV in 100 m For Systemic JIA < 30 kg: Tocilizumab 12 mg/kg IV in 100 m ≥ 30 kg: Tocilizumab 8 mg/kg IV in 100 m OTHER: LAB ORDERS CBC w/ diff, Platelets, AST and ALT at 2 must be a page of the pag	and here: all NS over 60 minutes every 4 week all NS over 60 minutes every 4 week all NS over 60 minutes every 2 wee all NS over 60 minutes every 2 week and infusion, then every 4 weeks	s (no less than 28 days) s (no less than 28 days) ks (no less than 14 days)	PRE-MEDICATIONS PO Acetaminophen: 650 mg Cetirizine: 10 mg Diphenhydramine: 25 mg IV Methylprednisolone: 125 mg Diphenhydramine: 25 mg OTHER:
Lipid panel at 2nd infusion, then every 6 of OTHER LAB:			
REFILL X 12 MONTHS UNLESS OTHERW Patient to be observed for 30 minutes following the first in the event of an adverse reaction occurring in the infusior PRESCRIBER INFORMATION	/ISE NOTED HERE:fusion. n clinic, utilize the Immersiv Health adverse rea		
PROVIDER NAME:			NPI #:
EMAIL:		PHONE:	FAX:
ADDRESS (INCLUDE CITY, STATE, ZIP):			
SUPERVISING PHYSICIAN: [(FAPPLICABLE)	CONTACT NAME:		
SIGNATURE: (NO STAMPS) SUBSTITUTION F	·		DATE: